7th Annual USC Multi-Disciplinary Breast Cancer Symposium


 

Combined Inhibition of Endocrine Therapy and the PI3K/AKT/mTOR Pathways Appears Superior to Either Component in HR+ Metastatic Breast Cancer

279 views
May 27, 2020
Comments 0
Login to view comments. Click here to Login